Your browser doesn't support javascript.
loading
Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update.
Armaiz-Pena, Gustavo; Flores, Shahida K; Cheng, Zi-Ming; Zhang, Xhingyu; Esquivel, Emmanuel; Poullard, Natalie; Vaidyanathan, Anusha; Liu, Qianqian; Michalek, Joel; Santillan-Gomez, Alfredo A; Liss, Michael; Ahmadi, Sara; Katselnik, Daniel; Maldonado, Enrique; Salgado, Sarimar Agosto; Jimenez, Camilo; Fishbein, Lauren; Hamidi, Oksana; Else, Tobias; Lechan, Ron; Tischler, Art S; Benn, Diana E; Dwight, Trisha; Clifton-Bligh, Rory; Sanso, Gabriela; Barontini, Marta; Vincent, Deepa; Aronin, Neil; Biondi, Bernadette; Koops, Maureen; Bowhay-Carnes, Elizabeth; Gimenez-Roqueplo, Anne-Paule; Alvarez-Eslava, Andrea; Bruder, Jan M; Kitano, Mio; Burnichon, Nelly; Ding, Yanli; Dahia, Patricia L M.
Afiliação
  • Armaiz-Pena G; Division of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
  • Flores SK; Division of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
  • Cheng ZM; Division of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
  • Zhang X; Division of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
  • Esquivel E; Division of Hematology and Medical Oncology, Department of Medicine, UTHSA, San Antonio, Texas.
  • Poullard N; Mays Cancer Center, UTHSA, San Antonio, Texas.
  • Vaidyanathan A; Mays Cancer Center, UTHSA, San Antonio, Texas.
  • Liu Q; Department of Population Health Sciences, UTHSA, San Antonio, Texas.
  • Michalek J; Department of Population Health Sciences, UTHSA, San Antonio, Texas.
  • Santillan-Gomez AA; Division of Surgical Oncology, Department of Surgery, UTHSA, San Antonio, Texas.
  • Liss M; Department of Urology, UTHSA, San Antonio, Texas.
  • Ahmadi S; Division of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
  • Katselnik D; Diabetes and Metabolism Specialists, San Antonio, Texas, USA.
  • Maldonado E; Division of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
  • Salgado SA; Department Endocrine Neoplasia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jimenez C; Department Endocrine Neoplasia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Fishbein L; Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
  • Hamidi O; Division of Endocrinology and Metabolism, UT Southwestern Medical Center, Dallas, Texas.
  • Else T; Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
  • Lechan R; Tufts Medical Center, Boston, Massachusetts.
  • Tischler AS; Tufts Medical Center, Boston, Massachusetts.
  • Benn DE; Cancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia.
  • Dwight T; Cancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia.
  • Clifton-Bligh R; Cancer Genetics, Kolling Institute, Royal North Shore Hospital and University of Sydney, Sydney, NSW, Australia.
  • Sanso G; Center for Endocrinological Investigations (CEDIE), Hospital de Niños R. Gutiérrez, Buenos Aires, C1425EFD Argentina.
  • Barontini M; Center for Endocrinological Investigations (CEDIE), Hospital de Niños R. Gutiérrez, Buenos Aires, C1425EFD Argentina.
  • Vincent D; Division of Endocrinology, University of Massachusetts, Worcester, Massachusetts.
  • Aronin N; Division of Endocrinology, University of Massachusetts, Worcester, Massachusetts.
  • Biondi B; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Koops M; Division of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
  • Bowhay-Carnes E; Mays Cancer Center, UTHSA, San Antonio, Texas.
  • Gimenez-Roqueplo AP; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Genetics Department, Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
  • Alvarez-Eslava A; University Health System, Texas Diabetes Institute, San Antonio, Texas.
  • Bruder JM; Division of Endocrinology, Department of Medicine, University of Texas Health San Antonio (UTHSA), San Antonio, Texas.
  • Kitano M; Mays Cancer Center, UTHSA, San Antonio, Texas.
  • Burnichon N; Division of Surgical Oncology, Department of Surgery, UTHSA, San Antonio, Texas.
  • Ding Y; Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Genetics Department, Université de Paris, PARCC, INSERM, Equipe Labellisée par la Ligue contre le Cancer, Paris, France.
  • Dahia PLM; Department of Pathology, UTHSA, San Antonio, Texas.
J Clin Endocrinol Metab ; 106(1): e350-e364, 2021 01 01.
Article em En | MEDLINE | ID: mdl-33051659
ABSTRACT

PURPOSE:

This work aimed to evaluate genotype-phenotype associations in individuals carrying germline variants of transmembrane protein 127 gene (TMEM127), a poorly known gene that confers susceptibility to pheochromocytoma (PHEO) and paraganglioma (PGL).

DESIGN:

Data were collected from a registry of probands with TMEM127 variants, published reports, and public databases. MAIN OUTCOME

ANALYSIS:

Clinical, genetic, and functional associations were determined.

RESULTS:

The cohort comprised 110 index patients (111 variants) with a mean age of 45 years (range, 21-84 years). Females were predominant (76 vs 34, P < .001). Most patients had PHEO (n = 94; 85.5%), although PGL (n = 10; 9%) and renal cell carcinoma (RCC, n = 6; 5.4%) were also detected, either alone or in combination with PHEO. One-third of the cases had multiple tumors, and known family history was reported in 15.4%. Metastatic PHEO/PGL was rare (2.8%). Epinephrine alone, or combined with norepinephrine, accounted for 82% of the catecholamine profiles of PHEO/PGLs. Most variants (n = 63) occurred only once and 13 were recurrent (2-12 times). Although nontruncating variants were less frequent than truncating changes overall, they were predominant in non-PHEO clinical presentations (36% PHEO-only vs 69% other, P < .001) and clustered disproportionately within transmembrane regions (P < .01), underscoring the relevance of these domains for TMEM127 function. Integration of clinical and previous experimental data supported classification of variants into 4 groups based on mutation type, localization, and predicted disruption.

CONCLUSIONS:

Patients with TMEM127 variants often resemble sporadic nonmetastatic PHEOs. PGL and RCC may also co-occur, although their causal link requires further evaluation. We propose a new classification to predict variant pathogenicity and assist with carrier surveillance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feocromocitoma / Neoplasias das Glândulas Suprarrenais / Proteínas de Membrana Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Feocromocitoma / Neoplasias das Glândulas Suprarrenais / Proteínas de Membrana Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Endocrinol Metab Ano de publicação: 2021 Tipo de documento: Article